Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 14/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 14/20 | 0.64 |
| ▸ | PDE4A | P27815 | 2/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.58 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | GALR3 | O60755 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496001 | 0.87 | PDE3B (0.65) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10353457 | 0.86 | PDE3B (0.71) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7508831 | 0.83 | PDE3B (0.64) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9686736 | 0.82 | PDE3B (0.60) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL934905 | 0.82 | PDE3B (0.62) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL6856944 | 0.82 | PDE3B (0.62) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7327355 | 0.82 | PDE3B (0.66) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL2840668 | 0.82 | PDE3B (0.66) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7338020 | 0.82 | PDE3B (0.66) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL5681256 | 0.82 | PDE3B (0.62) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628972-B1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-04-22 | — | — | EP | claimed |
| US-7365088-B2 | Indazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-29 | — | — | US | claimed |
| EP-1628972-A1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-01 | — | — | EP | claimed |
| US-20040235824-A1 | Indazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | US | claimed |
| WO-2004101556-A1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | claimed |
| EP-1479675-A1 | Indazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | claimed |
| EP-1628972-B1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-04-22 | — | — | EP | disclosed |
| US-7365088-B2 | Indazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-29 | — | — | US | disclosed |
| EP-1628972-A1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-01 | — | — | EP | disclosed |
| US-20040235824-A1 | Indazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | US | disclosed |
| WO-2004101556-A1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-1479675-A1 | Indazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
| EP-1272474-A1 | SUBSTITUTED 5-METHYLDIHYDROPYRIDAZINONES AND THEIR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF ANEMIAS | Bayer Aktiengesellschaft (DE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001064652-A1 | SUBSTITUTED 5-METHYLDIHYDROPYRIDAZINONES AND THEIR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF ANEMIAS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235824-A1 | Indazole-derivatives as factor Xa inhibitors | F11, F12, F5 | PDE3B 146/4885PDE3A 167/4885PDE4A 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.